Strongbridge Biopharma plc announced the expansion of its rare disease commercial capabilities with the hiring of Dave Bonnell, senior vice president of sales and marketing, and Scott Wilhoit, senior vice president, global market access and patient services. Dave will be responsible for sales and marketing efforts, including the construction of an experienced rare disease sales force, and Scott will lead all aspects of market access, including reimbursement and patient services. Dave before joining Strongbridge, he served as vice president, rare disease and GI specialty sales at Shire Pharmaceuticals. Scott brings nearly 30 years of industry experience, most of which has been focused within market and patient access in the rare disease category. He most recently served as vice president, market and patient access at Marathon Pharmaceuticals.